Pressure-Based Volume Measurement Technology for In-process Measurement of Microplate Contents
Poster Feb 10, 2015
John Thomas Bradshaw, Bill Gigante, Christoph Schwedes
Modern drug discovery and research labs are utilizing complex automation systems to assist in high throughput screening of novel drug candidates. A large portion of these laboratories are using ANSI-SBS-standard 96- and 384-well plates to achieve the necessary throughput. The vol¬ume of sample transferred into and out of these plates can be critical to the success of assays or validation of procedures. One specific example is in the preparation of mother/daughter plates from compounds pulled from library stores. It is not uncommon to find a compound storage tube containing less volume than expected, which in turn may result in incorrect volumes delivered to mother plates to be used for screening tests. A simple approach to determining volumes in these prepared mother plates is needed.
Using a new pressure-based volume measurement technology, it is now possible to make direct measurements of volumes in microplates. This new measurement technology is found in the Artel SDS, which provides precise and accurate volume measurements in 96- and 384-well micro¬plates. The SDS technology determines well volume by sealing and pressurizing individual wells and is able to accurately and repeatedly measure the contents of a well without regard to the shape of the well, type of plastic, color of material, or type of sample.
Using four common plate types and a variety of precision metal cylinders of known volume, the basic operational principles of this volume measurement technology is demonstrated herein.
We found a distinct subpopulation of Tregs within BMSCs. Tregs and BMSCs in co-culture conferred neuroprotection that varied in a dose-dependent manner. Tregs minimized stem cell production of IL-6, a pro-inflammatory cytokine, and inhibited BMSC secretion of FGF-beta, a cytokine related to BMSC proliferation and differentiation. The ratio of Tregs found natively in BMSCs is optimally adapted to provide the maximum neuroprotective benefit of stem cell treatment after ischemic stroke.READ MORE